"The president is right to make this the center point of the rising and sustained trade conflict," says Sen. Chris Coons.Politicsread more
James Bullard said he dissented on this week's Fed decision to lower rates by a quarter percentage point because he didn't think the cut was big enough.The Fedread more
More than 400 Chinese products will be temporarily exempted from tariffs that President Donald Trump's administration imposed last year.China Economyread more
"I feel like I've contributed all I can to this primary election," he told MSNBC's "Morning Joe." "And it's clearly not my time. So I'm going to end my presidential campaign."2020 Electionsread more
Apple will get a taste of whether upgraded features on the new iPhone 11 are enough to lure shoppers to retail stores around the world as the new smartphones officially hit...Technologyread more
Joshua Harris, Apollo Global Management's co-founder, has a message for private equity's naysayers in Washington.Delivering Alpharead more
Roku shares have more than quadrupled this year, but the stock has had some rocky days of late as more players jump into streaming.Technologyread more
Two sites were hit Saturday — the Abqaiq and Khurais oil facilities — which took out 5.7 million barrels per day of oil production.World Politicsread more
Apple CEO Tim Cook greeted iPhone 11 customers at the reopening of the Fifth Avenue Apple store on Friday. CNBC also took a tour inside. Here's a look.Technologyread more
J.C. Penney is preparing for talks with its creditors on ways it can ease its debt load, buying the retailer some time ahead of the critical holiday shopping season, Bloomberg...Retailread more
Pivotal Research Group began coverage of Roku with a sell rating on FridayInvestingread more
Johnson & Johnson's sales in India dipped 3 percent in the year to March 2018, a regulatory filing showed on Thursday, as the U.S. drugmaker grappled with the country's stringent medical device pricing policies.
The company, currently mired in a controversy surrounding the safety of its baby talcum powder, reported overall sales of 58.28 billion rupees ($829 million) in India for the year, its filing with the country's Ministry of Corporate Affairs shows.
But its after-tax profit for the period rose 18 percent to $98 million on other income, including foreign exchange gains.
J&J's medical device sales in India have been hit following the federal government's move in 2017 to cap prices of devices such as orthopaedic knee implants to help poor patients.
The restrictions were part of a broader push by India to end what it called "illegal profiteering" by companies.
The company has recently been in the news after a Reuters investigation found J&J knew for decades that cancer-causing asbestos lurked in its baby powder.
The report prompted drug inspectors across India to collect talc samples from J&J facilities for testing.
J&J has said the Reuters article was "one-sided, false and inflammatory", adding that its Baby Powder was "safe and asbestos free".
J&J's Baby Powder is one of the most recognised foreign brands in India. The company leads sales in the Indian baby and child toiletries market, which Euromonitor International estimates was worth $178 million last year.
J&J's consumer segment in India, which includes baby care products such as soap and talc, recorded sales of 31 billion rupees in the year to March 2018, marginally lower than the previous year, the company's India filing showed.
Sales in its medical segment, which includes its orthopaedic products, fell 7 percent to 19.6 billion rupees.